These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33628162)

  • 1. Insights into the actions of angiotensin-1 receptor (AT1R) inverse agonists: Perspectives and implications in COVID-19 treatment.
    Heimfarth L; Dos Santos MA; Barreto-Filho JA; Barreto AS; Macedo FN; Araújo AAS; Martins-Filho P; Scotti MT; Scotti L; Quintans-Júnior LJ
    EXCLI J; 2021; 20():252-275. PubMed ID: 33628162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The place of ARBs in heart failure therapy: is aldosterone suppression the key?
    Markan U; Pasupuleti S; Pollard CM; Perez A; Aukszi B; Lymperopoulos A
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719868134. PubMed ID: 31401939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
    Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults.
    Dorosch T; Ganzer CA; Lin M; Seifan A
    Curr Pain Headache Rep; 2019 Sep; 23(11):85. PubMed ID: 31515634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
    Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
    Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
    Baral R; White M; Vassiliou VS
    Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.
    Takezako T; Unal H; Karnik SS; Node K
    Pharmacol Res; 2017 Sep; 123():40-50. PubMed ID: 28648738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular docking, molecular dynamics, and
    Alnajjar R; Mostafa A; Kandeil A; Al-Karmalawy AA
    Heliyon; 2020 Dec; 6(12):e05641. PubMed ID: 33294721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
    Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
    Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint.
    Cappuccio FP; Siani A
    Nutr Metab Cardiovasc Dis; 2020 Jul; 30(8):1227-1235. PubMed ID: 32595085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.
    Matsuzawa Y; Ogawa H; Kimura K; Konishi M; Kirigaya J; Fukui K; Tsukahara K; Shimizu H; Iwabuchi K; Yamada Y; Saka K; Takeuchi I; Hirano T; Tamura K
    Hypertens Res; 2020 Nov; 43(11):1257-1266. PubMed ID: 32820236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
    Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X
    BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
    Vázquez-Cornejo E
    Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe?
    Shyh GI; Nawarskas JJ; Cheng-Lai A
    Cardiol Rev; 2020; 28(4):213-216. PubMed ID: 32496364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors.
    Golpe R; Pérez-de-Llano LA; Dacal D; Guerrero-Sande H; Pombo-Vide B; Ventura-Valcárcel P;
    Med Clin (Barc); 2020 Dec; 155(11):488-490. PubMed ID: 32651067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
    Pirola CJ; Sookoian S
    J Infect; 2020 Aug; 81(2):276-281. PubMed ID: 32474043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease.
    Gommans DHF; Nas J; Pinto-Sietsma SJ; Koop Y; Konst RE; Mensink F; Aarts GWA; Konijnenberg LSF; Cortenbach K; Verhaert DVM; Thannhauser J; Mol JQ; Rooijakkers MJP; Vos JL; van Rumund A; Vart P; Hassing RJ; Cornel JH; de Jager CPC; van den Heuvel MM; van der Hoeven HG; Verbon A; Pinto YM; van Royen N; van Kimmenade RRJ; ; de Leeuw PW; van Agtmael MA; Bresser P; ; van Gilst WH; Vonk-Noordergraaf A; Tijssen JGP; ; van Royen N; de Jager CPC; van den Heuvel MM; van der Hoeven HG; Verbon A; Pinto YM; van Kimmenade RRJ
    Am Heart J; 2020 Aug; 226():60-68. PubMed ID: 32512291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.
    Dworakowska D; Grossman AB
    J Physiol Pharmacol; 2020 Apr; 71(2):. PubMed ID: 32633235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.